Loading...
NEIMETH logo

Neimeth International Pharmaceuticals Community

NGSE:NEIMETH Community
  • 1 Narratives written by author
  • 7 Comments on narratives written by author
  • 16 Fair Values set on narratives written by author

Community Investing Ideas

NEIMETH logo
Neimeth International Pharmaceuticals

Neimeth Pharmaceuticals Delivers Strong Turnaround in H1 2025 Despite Financing Cost Pressures

Neimeth Pharmaceuticals Delivers Strong Turnaround in H1 2025 Despite Financing Cost Pressures Neimeth International Pharmaceuticals Plc posted a robust recovery in its half-year 2025 earnings, underpinned by strong revenue growth and operational efficiency, despite the lingering drag of elevated finance costs. Key Highlights: Revenue Surge : Neimeth reported a 76% year-on-year increase in revenue to ₦2.91 billion in H1 2025, up from ₦1.66 billion in H1 2024.
View narrative
₦7.38
FV
16.0% undervalued intrinsic discount
5.00%
Revenue growth p.a.
0users have liked this narrative
7users have commented on this narrative
12users have followed this narrative
about 2 months ago author updated this narrative